Vesicular stomatitis virus-based vaccines provide cross-protection against andes and sin nombre viruses

Bryce M. Warner, Derek R. Stein, Rohit K. Jangra, Megan M. Slough, Patrycja Sroga, Angela Sloan, Kathy L. Frost, Stephanie Booth, Kartik Chandran, David Safronetz

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Andes virus (ANDV) and Sin Nombre virus (SNV) are the main causative agents responsible for hantavirus cardiopulmonary syndrome (HCPS) in the Americas. HCPS is a severe respiratory disease with a high fatality rate for which there are no approved therapeutics or vaccines available. Some vaccine approaches for HCPS have been tested in preclinical models, but none have been tested in infectious models in regard to their ability to protect against multiple species of HCPS-causing viruses. Here, we utilize recombinant vesicular stomatitis virus-based (VSV) vaccines for Andes virus (ANDV) and Sin Nombre virus (SNV) and assess their ability to provide cross-protection in infectious challenge models. We show that, while both rVSVDG/ANDVGPC and rVSVDG/SNVGPC display attenuated growth as compared to wild type VSV, each vaccine is able to induce a cross-reactive antibody response. Both vaccines protected against both homologous and heterologous challenge with ANDV and SNV and prevented HCPS in a lethal ANDV challenge model. This study provides evidence that the development of a single vaccine against HCPS-causing hantaviruses could provide protection against multiple agents.

Original languageEnglish (US)
Article number645
Issue number7
StatePublished - Jul 2019


  • Andes virus
  • Hantavirus
  • Hantavirus cardiopulmonary syndrome
  • Prophylactic immunization
  • Sin Nombre virus
  • Vaccination
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology


Dive into the research topics of 'Vesicular stomatitis virus-based vaccines provide cross-protection against andes and sin nombre viruses'. Together they form a unique fingerprint.

Cite this